For further information, refer to the consolidated financial statements and related notes included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended September 30, 2017.
Manta has annualized sales of approximately $8 million.
Based on the preliminary purchase price allocation, the Company recorded approximately $0.4 million of accounts receivable, $1.1 million of inventory, $0.2 million of property, plant and equipment, $0.4 million of accounts payable and accrued expenses, $3.5 million of goodwill, $1.2 million of tradenames and $3.5 million of amortizable intangible assets consisting of customer relationships with a weighted average life of 13 years.
The Company provides compensation benefits to certain key employees under several share-based plans providing for performance-accelerated restricted shares (restricted shares), and to non-employee directors under a non-employee directors compensation plan.
There were 316,544 non-vested shares outstanding as of June 30, 2018.
Compensation expense related to the non-employee director grants was $0.3 million and $0.8 million for the three and nine-month periods ended June 30, 2018, respectively, and $0.3 million and $0.8 million for the corresponding periods of 2017.
EBIT is defined as earnings before interest and taxes.
EBIT on a consolidated basis is a non-GAAP financial measure.References to the third quarters of 2018 and 2017 represent the three-month periods ended June 30, 2018 and 2017, respectively.
In the third quarter of 2018, sales, net earnings and diluted earnings per share were $192.2 million, $19.0 million and $0.73 per share, respectively, compared to $171.2 million, $12.6 million and $0.49 per share, respectively, in the third quarter of 2017.
The increase in the third quarter of 2018 compared to the third quarter of 2017 was mainly due to the sales contributions from the NRG, Morgan Schaffer and Vanguard Instruments acquisitions.
In the third quarter of 2018, net sales of $22.0 million were $1.6 million, or 7.7%, higher than the $20.4 million in the third quarter of 2017.
Backlog was $425.5 million at June 30, 2018 compared with $377.1 million at September 30, 2017.
Of the new orders received in the first nine months of 2018, $219.1 million related to Filtration products, $144.2 million related to Test products, $168.0 million related to USG products, and $57.6 million related to Technical Packaging products.
Amortization expenses consist of amortization of acquired intangible assets from acquisitions and other identifiable intangible assets (primarily software).
The principal components in other expenses, net, in the first nine months of 2018 were $2.1 million of charges primarily related to the USG segment restructuring activities, including the Doble facility consolidations, partially offset by gains on derivative instruments.
The restructuring charges mainly related to severance and compensation benefits, professional fees and asset impairment charges related to abandoned assets.
The principal component in other income, net, in the first nine months of 2017 was $0.4 million of income related to death benefit insurance proceeds from a former subsidiary.